Source - SMW
Hikma Pharmaceuticals' wholly-owned US subsidiary, West-Ward Pharmaceuticals Corp, has launched Flucytosine Capsules USP in 250mg and 500mg strengths, the generic equivalents to Ancobon.  

West-Ward's Flucytosine Capsules USP are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.   

Hikma said that according to IMS Health, US sales of Flucytosine Capsules USP in 250mg and 500mg strengths were approximately $47 million for the 12 months ending September 2017.  

President of generics Brian Hoffmann said: 'We are very pleased to be launching this product from the West-Ward Columbus portfolio. 

'We have an excellent pipeline of differentiated products that we expect will drive future growth.'  


At 9:14am: (LON:HIK) Hikma Pharmaceuticals PLC share price was -4p at 1114p



Related Charts

Hikma Pharmaceuticals (HIK)

0.00 (0.00%)
delayed 17:30PM